dr gulick infectious diseasedr gulick infectious disease

Anthony R. Cillo, Benedict B. Hilldorfer, Christina M. Lalama, John E. McKinnon, Robert W. Coombs, Allan R. Tenorio, Lawrence Fox, Rajesh T. Gandhi, Heather J. Ribaudo, Judith S. Currier, Roy M. Gulick, Timothy J. Wilkin, John W. Mellors. Insurance About Me Hospitals. Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. Prior to 2020, the S. sonnei strain had always been dominant. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women, Raphael J. Landovitz, Deborah Donnell, Meredith E. Clement, Brett Hanscom, Leslie Cottle, Lara E. Coelho, Robinson Cabello, Suwat Chariyalertsak, Eileen F. Dunne, Ian Frank, Jorge A Gallardo-Cartagena, Aditya H Gaur, Pedro Gonzales, Ha V Tran, Juan C Hinojosa, Esper G Kallas, Colleen F Kelley, Marcelo H. Losso, J Valdez Madruga, Keren Middelkoop, Nittaya Phanuphak, Breno Santos, Omar Sued, Javier Valencia Huaman, Edgar T. Overton, Shobha Swaminathan, Carlos del Rio, Roy M. Gulick, Paul G. Richardson, Philip Sullivan, Estelle Piwowar-Manning, Mark A. Marzinke, Craig W. Hendrix, Maoji Li, Zhe Wang, Jeanne M. Marrazzo, Eric S. Daar, Aida Asmelash, Todd T. Brown, Peter J. Anderson, Susan H. Eshleman, Marcus Bryan, Cheryl Blanchette, Jonathan Lucas, Christina Psaros, Steven A. Safren, Jeremy Sugarman, Hyman M. Scott, Joseph J. Eron, Sheldon D. Fields, Nirupama Sista, Kailazarid Gomez-Feliciano, Andrea Jennings, Ryan Kofron, Timothy H. Holtz, Katherine Shin, James F. Rooney, Kimberly Y. Smith, William Spreen, David J. Margolis, Alex R. Rinehart, Adeola Adeyeye, Myron S. Cohen, Marybeth McCauley, Beatriz Grinsztejn, Hptn (PopART) Study Team. 2316 S Cedar St, Lansing, MI. There are established guidelines for using common antibiotics to treat shigellosis, but the obvious challenge is that emerging extensively drug-resistant shigella strains are resistant to all of these recommended agents, Dr. Louise Francois Watkins, medical officer with the National Antimicrobial Resistance Monitoring System for Enteric Bacteria Team, said on the CDC call. Preparing for your first cancer appointment can be overwhelming. Interferon--Mediated Activation of T Cells from Healthy and HIV-Infected Individuals Is Suppressed by 9-Tetrahydrocannabinol. Roy M. Gulick, Timothy J. Wilkin, Ying Q. Chen, Raphael J. Landovitz, K. Rivet Amico, Alicia M. Young, Paul G. Richardson, Mark A. Marzinke, Craig W. Hendrix, Susan H. Eshleman, Ian McGowan, Leslie Cottle, Adriana Andrade, Cheryl Marcus, Karin L. Klingman, Wairimu Chege, Alex R. Rinehart, James F. Rooney, Philip Andrew, Robert A. Salata, Marc O. Siegel, Yukari C. Manabe, Ian Frank, Ken K. Y. Ho, Jorge Santana, Joanne D. Stekler, Shobha Swaminathan, Marybeth McCauley, Sally Hodder, Kenneth H. Mayer, Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants, Katie R. Mollan, Camlin Tierney, Jacklyn N. Hellwege, Joseph J. Eron, Michael G. Hudgens, Roy M. Gulick, Richard Haubrich, Paul E. Sax, Thomas B. Campbell, Eric S. Daar, Kevin Robertson, Diana Ventura, Qing Ma, Digna R. Velez Edwards, David W. Haas, Antibody 10-1074 suppresses viremia in HIV-1-infected individuals, Marina Caskey, Till Schoofs, Henning Gruell, Allison Settler, Theodora K. Karagounis, Edward F. Kreider, Ben Murrell, Nico Pfeifer, Lilian Nogueira, Thiago Y. Oliveira, Gerald H. Learn, Yehuda Z. Cohen, Clara Lehmann, Daniel Gillor, Irina Shimeliovich, Cecilia Unson-OBrien, Daniela Weiland, Alexander. Barriers to Uptake of Long-Acting Antiretroviral Products for Treatment and Prevention of Human Immunodeficiency Virus (HIV) in High-Income Countries. Thomas B. Campbell, Laura M. Smeaton, N. Kumarasamy, Timothy P. Flanigan, Karin L. Klingman, Cynthia Firnhaber, Beatriz Grinsztejn, Mina C. Hosseinipour, Johnstone Kumwenda, Umesh G. Lalloo, Cynthia Riviere, Jorge Sanchez, Marineide Gonalves de Melo, Khuanchai Supparatpinyo, Srikanth Tripathy, Ana Martinez, Apsara Nair, Ann Walawander, Laura Moran, Yun Chen, Wendy Snowden, James F. Rooney, Jonathan Uy, Robert T. Schooley, Victor De Gruttola, James Hakim, Edith Swann, Ronald L. Barnett, Barbara Brizz, Yvette Delph, Nikki Gettinger, Ronald T. Mitsuyasu, Susan H. Eshleman, Steven A. Safren, Susan A. Fiscus, Adriana Andrade, David W. Haas, Farida Amod, Vladimir Berthaud, Robert C. Bollinger, Yvonne J. Bryson, David D. Celentano, David Chilongozi, Myron S. Cohen, Ann C. Collier, Judith S. Currier, Susan Cu-Uvin, Joseph J. Eron, Charles Flexner, Joel E. Gallant, Roy M. Gulick, Scott M. Hammer, Irving F. Hoffman, Peter N. Kazembe, Newton Kumwenda, Javier R. Lama, Jody Lawrence, Chiedza Maponga, Francis Martinson, Kenneth H. Mayer, Karin Nielsen, Richard B. Pendame, Bharat Ramratnam, Ian Sanne, Patrice Severe, Thira Sirisanthana, Suniti Solomon, Steve Tabet, Taha E. Taha, Charles van der Horst, Christine Wanke, Joan Gormley, Cheryl Marcus, Beverly Putnam, Smanga Ntshele, Edde Loeliger, Keith A. Pappa, Nancy Webb, David Shugarts, Mark A. Winters, Renard S. Descallar, Joseph Steele, Michael Wulfsohn, Farideh Said, Yue Chen, John Martin, Norbert Bischofberger, Andrew K. Cheng, Howard Jaffe, Jabin Sharma, Selvamuthu Poongulali, Sandra W. Cardoso, Deise Lucia Faria, Sima Berendes, Kelly Burke, Rosie Mngqibisa, Cecilia Kanyama, Virginia Kayoyo, Wadzanai Samaneka, Anthony Chisada, Sharla Faesen, Suwat Chariyalertsak, Breno Santos, Rita Alves Lira, Anjali A. Joglekar, Alberto La Rosa, Rosa Infante, Mamta K. Jain, T. Petersen, Sheela Godbole, Sampada Dhayarkar, Judith Feinberg, Jenifer Baer, Richard B. Pollard, David M. Asmuth, Raman R. Gangakhedkar, Asmita Gaikwad, M. Graham Ray, Cathi Basler, Michael F. Para, Kathy J. Watson, Babafemi Taiwo, Donna V. McGregor, Henry H. Balfour, Beth D. Mullan, Ge Youl Kim, Michael K. Klebert, Gary M. Cox, Martha Silberman, Donna Mildvan, Manuel Revuelta, Karen T. Tashima, Helen Patterson, P. Jan Geiseler, Bartolo Santos, Eric S. Daar, Ruben Lopez, Laurie Frarey, David Currin, David H. Haas, Vicki L. Bailey, Pablo Tebas, Larisa Zifchak, Jolene Noel-Connor, Madeline Torres, Beverly E. Sha, Janice M. Fritsche, Michelle S. Cespedes, Janet Forcht, William A. O'Brien, Cheryl Mogridge, Christine Hurley, Roberto Corales, Maria Palmer, Mary Adams, Amneris E. Luque, Luis Lopez-Detres, Todd Stroberg, Vicriviroc Resistance Decay and Relative Replicative Fitness in HIV-1 Clinical Isolates Under Sequential Drug Selection Pressures, Athe M. N. Tsibris, Zixin Hu, Roger Paredes, Kay E. Leopold, Opass Putcharoen, Allison L. Schure, Natalie I Mazur, Eoin Coakley, Zhaohui Su, Roy M. Gulick, Daniel R. Kuritzkes, Virologic, clinical and immunologic responses following failure of first-line antiretroviral therapy in Haiti, Macarthur Charles, Paul Leger, Patrice Severe, Colette Guiteau, Alexandra Apollon, Roy M. Gulick, Warren D. Johnson, Jean W. Pape, Daniel W. Fitzgerald, Nina Mani, Jeffrey Murray, Roy M Gulick, Filip Josephson, Veronica Miller, Peter Miele, Jur Strobos, Kimberly Struble, Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small Molecule CCR5 Antagonists, Timothy J. Henrich, Nicolas Lewine, Sun Hee Lee, Suhas S.P. Dr. Peter Gulick graduated from Chicago College Of Osteopathic Medicine in 1972. HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug, Opass Putcharoen, Sun Hee Lee, Timothy J. Henrich, Zixin Hu, Jakapat Vanichanan, Eoin Coakley, Wayne Greaves, Roy M. Gulick, Daniel R. Kuritzkes, Athe M. N. Tsibris, CCR5 antagonism in HIV infection: Current concepts and future opportunities, Cost-effectiveness of adding an agent that improves immune responses to initial antiretroviral therapy (ART) in HIV-infected patients: guidance for drug development, Bethany L. Morris, Callie A. Scott, Timothy J. Wilkin, Paul E. Sax, Roy M. Gulick, Kenneth A. Freedberg, Bruce R. Schackman, Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: Results from the AIDS Clinical Trials Group Study A5095, Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA, Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants, Holzinger ER, Grady B, Ritchie MD, Ribaudo HJ, Acosta EP, Morse GD, Gulick RM, Robbins GK, Clifford DB, Daar ES, McLaren P, Haas DW, Next-generation oral preexposure prophlaxis: beyond tenofovir, HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that correct in the presence of drug, Putcharoen O, Lee SH, Henrich T, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick R, Kuritzkes D, Tsibris A, Morris BL, Scott CA, Wilkin TJ, Sax PE, Gulick RM, Freedberg KA, Schackman BR, Differential use of CCR5 by HIV-1 clinical isolates resistant to small molecule CCR5 antagonists, Henrich TJ, Lewine NRP, Lee S-H, Rao SSP, Berro R, Gulick RM, Moore JP, Tsibris AMN, Kuritzkes DR, Novel clinical trials designs for the development of new antiretroviral agents, Mani N, Murray J, Gulick RM, Josephson F, Miller V, Miele P, Strobos J, Struble K, Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures, Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure A, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR, Charles M, Leger PD, Severe P, Guiteau C, Apollon A, Gulick RM, Johnson WD, Pape JW, Fitzgerald DW, A pilot trial of adding maraviroc to suppressive antiretroviral therapy for suboptimal CD4+ T-cell recovery despite sustained virologic suppression: ACTG A5256, Wilkin TJ, Lalama CM, McKinnon J, Gandhi RT, Lin N, Landay A, Ribaudo H, Fox L, Currier JS, Mellors JW, Gulick R, Tenorio AR. HIV treatment strategies: planning for the long term. Looking for something else? Preparing for your first cancer appointment can be overwhelming. HIV Type 1 Chemokine Coreceptor Use among Antiretroviral-Experienced Patients Screened for a Clinical Trial of a CCR5 Inhibitor: AIDS Clinical Trial Group A5211, Timothy J. Wilkin, Zhaohui Su, Daniel R. Kuritzkes, Michael Hughes, Charles Flexner, Robert E. Gross, Eoin Coakley, Wayne Greaves, Catherine Godfrey, Paul R. Skolnik, Joseph Timpone, Benigno Rodriguez, Roy M. Gulick, Antiretroviral Management of Treatment-Naive Patients, HIV-1 chemokine coreceptor usage among antiretroviral-experienced patients screening for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group 5211, Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM, Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir/ritonavir treatment, Landay A, da Silva BA, King MS, Albrecht M, Benson C, Eron J, Glesby M, Gulick R, Hicks C, Kessler H, Murphy R, Thompson M, Clinton White A Jr, Wolfe P, McMillan FI, Hanna GJ, Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s, Kuritzkes DR, Ribaudo HJ, Squires KE, Koletar SL, Santana J, Riddler SA, Reichman R, Shikuma C, Meyer WA, Klingman K, Gulick RM, Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 infection (AIDS Clinical Trials Group Study A5095), Shikuma CM, Yang Y, Glesby MJ, Meyer WA, Tashima KT, Ribaudo HJ, Webb N, Bastow B, Kuritzkes DR, Gulick RM, Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virologic suppression, Gulick RM, Lalama CM, Ribaudo HJ, Shikuma CM, Schackman BR, Schouten J, Squires KE, Koletar SL, Pilcher CD, Reichman RC, Klingman KL, Kuritzkes DR, Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359, Haubrich RH, Jiang H, Swanstrom R, Bates M, Katzenstein D, Petch L, Fletcher CV, Fiscus SA, Gulick RM, Phase II study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: ACTG 5211, Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR, Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: Results of ACTG A5095, Schackman BR, Ribaudo HJ, Krambrink A, Hughes V, Kuritzkes DR, Gulick RM, A Randomized Trial of Treatment Interruption before Optimized Antiretroviral Therapy for Persons with Drug-Resistant HIV: 48-Week Virologic Results of ACTG A5086, Constance A. Benson, Florin Vaida, Diane V. Havlir, Gerald F. Downey, Michael M. Lederman, Roy M. Gulick, Marshall J. Glesby, Michael Wantman, Christian J. Bixby, Alex R. Rinehart, Sally Snyder, Rui Wang, Sheran S. Patel, Actg A Study Team. They're also typically reserved for "the most resistant infections that are out there," Gulick explains. Dr. Gulick has one office in New York where he specializes in Infectious Disease Medicine. The Uncertain Role of Corticosteroids in the Treatment of COVID-19. In 2009, he became the Chief of the Division of Infectious Diseases. Specialty Infectious Disease Medicine Your Rights and Protections Against Surprise Medical Bills, Stronger Together in the Face of COVID-19, A Second COVID-19 Booster: Your Questions Answered, Holiday Travel Safety Tips Amidst Emerging COVID-19 Variants, COVID-19 Vaccines: The Latest Science and Recommendations on Booster Shots, Updated Mask-Wearing Recommendations for Fully Vaccinated People, The COVID-19 Delta Variant: Heres What We Know So Far, What to Do About COVID-19 Vaccine Side Effects, Variants Could Be Keeping COVID-19 Numbers High, What to Do If Youre Fully Vaccinated For COVID-19, American Board of Internal Medicine (Infectious Disease), M.P.H., Harvard School of Public Health, 1993, M.D., Columbia University College of Physicians and Surgeons, 1986, AETNA -, Aetna Weill Cornell Employee Managed Care Plan, Aetna-NYP -, Empire Blue Cross/Blue Shield -, Empire Blue Cross/Blue Shield HealthPlus -, Health Insurance Plan of NY (HIP) -, Oxford Health Plans -, United Healthcare -, VNSNY CHOICE -. 1305 York Avenue 4th Floor. She is a graduate of NYU's Science, Health, and Environmental Reporting Program and has a background in psychology and neuroscience. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. Dr. Roy Gulick graduated from Columbia University College of Physicians and Surgeons in 1986. Prioritizing clinical research studies during the COVID-19 pandemic: lessons from New York City. IE 11 is not supported. Dr. Roy Gulick, MD is an Infectious Disease Specialist in New York, NY. They specialize in Infectious Disease Medicine, has 37 years of experience, and is board certified in Internal. While the infection is mild for most people, it can be serious for some vulnerable groups. Emily R. Holzinger, Benjamin J. Grady, Marylyn D. Ritchie, Heather J. Ribaudo, Edward P. Acosta, Gene D. Morse, Roy M. Gulick, Gregory K. Robbins, David B. Clifford, Eric S. Daar, Paul J. McLaren, David W. Haas. Change in high-sensitivity c-reactive protein levels following initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals. Cost-Effectiveness of Meningococcal Vaccination Among Men Who Have Sex With Men in New York City. Todd T. Brown, Krista Yuhas, Kenneth H. Mayer, Raphael J. Landovitz, Mark A. Marzinke, Craig W. Hendrix, Ying Q. Chen, Karen L. Klingman, Wairimu Chege, Marybeth McCauley, Roy M. Gulick, Timothy J. Wilkin. Dr. Roy M. Gulick, chief of the Division of Infectious Diseases at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine, and professor of medicine at Weill Cornell Medicine, answers questions about the new threat. Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine. Patrick O'Connell, Yuliya Pepelyayeva, Maja K Blake, Sean Hyslop, Robert B. Crawford, Michael D. Rizzo, Cristiane Pereira-Hicks, Sarah Godbehere, Linda Dale, Peter Gulick, Norbert E. Kaminski, Andrea Amalfitano, Yasser A. Aldhamen. Binglan Li, Yogasudha Veturi, Anurag Verma, Yuki Bradford, Eric S. Daar, Roy M. Gulick, Sharon A. Riddler, Gregory K. Robbins, Jeffrey L. Lennox, David W. Haas, Marylyn D. Ritchie. If your insurance carrier does not appear here please contact the doctors office as they may have individual contracts not included on this site. Combination therapy for patients with HIV-1 infection: the use of dual nucleoside analogues with protease inhibitors and other agents, Antiretroviral Therapy: Where are we going? Grant B Ellsworth, Marshall J. Glesby, Roy M. Gulick, Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment, Grant B Ellsworth, Leah A Burke, Martin T. Wells, Satish Mishra, Matthew Caffrey, David Liddle, Malika L. Madhava, Curtis O'Neal, Peter L. Anderson, Lane R. Bushman, Lucas Ellison, Josh Stein, Roy M. Gulick. Joseph E. Henriquez, Michael D. Rizzo, Robert B. Crawford, Peter Gulick, Norbert E. Kaminski. Relationship between latent and rebound viruses in a clinical trial of anti-HIV-1 antibody 3BNC117. 3 (2 ratings) Make an Appointment (212) 235-1519. Dr. Gulick received his undergraduate degree from Johns Hopkins University in 1982. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. David W. Haas, Heather J. Ribaudo, Richard B. Kim, Camlin Tierney, Grant R. Wilkinson, Roy M. Gulick, David B. Clifford, Todd Hulgan, Catia Marzolini, Edward P. Acosta. Dr. Peter Gulick, DO is a Medical Oncology Specialist in Lansing, MI. Dr. Roy Gulick, chief of the Division of Infectious Diseases in the Department of Medicine and professor of Medicine, received a "Lifetime Achievement Award for His Invaluable Contribution in the Field of HIV Medicine, Medical Education and Research," at the 2012 HIV Congress in Mumbai, India. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. John G. Gerber, Susan L. Rosenkranz, Yoninah Segal, Judith A. Aberg, Ronald D'Amico, Donna Mildvan, Roy M. Gulick, Valery Hughes, Charles Flexner, Francesca T. Aweeka, Ann Hsu, Joseph Gal, Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy, W. Huang, V De Gruttola, Margaret A. Fischl, Scott M. Hammer, Douglas D. Richman, Diane V. Havlir, Roy M. Gulick, Kathleen Squires, J. Mellors. Specialties Medical Oncology Infectious Disease Medicine Board Certifications Infectious Disease Internal Medicine Medical Oncology Learn why a board certification matters Awards Learn about the frequency of booster shots needed for maximum protection and how it can vary depending on the vaccine you received. He was promoted to Associate Professor of Medicine in 2001 and Professor of Medicine in 2007. Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. Lertora, Mark A. Beilke, David M. Mushatt, Russell Strada, Gildon N. Beall, Dena Duran, Mario Guerrero, Mark A. Jacobson, Judy Aberg, Glenna M. Auerback, Phyllis Barnett, Pablo Tebas, Genice Hamilton, Michael Royal, Lyle Oshita, Monica Millard, Scott Souza, Debra Ogata-Arakaki, Robert Delapenha, John Mc Neil, Lisa Alexis, Judith Brown, Elizabeth Gimbel, Ann Walawander, Kenneth Wood, Jeff Taylor, Bruce Peel, Jon Cook, Carol L. Brosgart, James F. Rooney, Cheryl N. Karol, Pascal J. de Caprariis, Jeanne Berg, Margo Heath-Chiozzi, Eugene Sun, Mark I. Becker, Ana Martinez, Robin Shepard, Melissa Kerkau, Joan Dragavon, Michelle Jack, Vivian Yuan, Robert W. Coombs, Antoinette Kenton, Sharon Shriver, Hongyu Jiang, The Pharmacokinetics of Amprenavir, Zidovudine, and Lamivudine in the Genital Tracts of Men Infected with Human Immunodeficiency Virus Type 1 (AIDS Clinical Trials Group Study 850), Arlene S. Pereira, Laura M. Smeaton, John G. Gerber, Edward P. Acosta, Sally Snyder, Susan A. Fiscus, Richard R. Tidwell, Roy M. Gulick, Robert L. Murphy, Joseph J. Eron, Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial, Scott M. Hammer, Florin Vaida, Kara Bennett, Mary K. Holohan, Lewis B. Sheiner, Joseph J. Eron, Lawrence Joseph Wheat, Ronald T. Mitsuyasu, Roy M. Gulick, Fred T. Valentine, Judith A. Aberg, Michael D. Rogers, Cheryl N. Karol, Alfred J. Saah, Ronald H. Lewis, Laura J. Bessen, Carol L. Brosgart, Victor DeGruttola, John W. Mellors, Safety and Antiviral Activity at 48 Weeks of Lopinavir/Ritonavir plus Nevirapine and 2 Nucleoside Reverse-Transcriptase Inhibitors in Human Immunodeficiency Virus Type 1-Infected Protease Inhibitor-Experienced Patients, Constance A. Benson, Steven G. Deeks, Scott C. Brun, Roy M. Gulick, Joseph J. Eron, Harold A. Kessler, Robert L. Murphy, Charles B. Hicks, Martin S. King, David Wheeler, Judith Feinberg, Richard Stryker, Paul E. Sax, Sharon A. Riddler, Melanie A. Thompson, Kathryn Real, Ann Hsu, Dale J. Kempf, Anthony J. Japour, Eugene Sun. AboutPressCopyrightContact. (editorial), Three- vs four-drug antiretroviral regimen for the initial treatment of HIV-1 infection: a randomized controlled trial, Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer III WA, Acosta EP, Schouten J, Squires KE, Pilcher CD, Murphy RL, Koletar SL, Carlson M, Reichman RC, Bastow B, Klingman KL, Kuritzkes DR. Design issues in initial HIV-treatment trials: focus on ACTG A5095. The spread of the Delta variant has put countries around the world on high alert. Dr. Gulick is Rochelle Belfer Professor in Medicine and Chief of the Division of Infectious Diseases at Weill Medical College of Cornell University, and Attending Physician at the New York Presbyterian Hospital in New York City. He currently serves as Co-Chair of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services and as Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. Learn what questions to ask your oncologist to better understand your diagnosis, treatment options and what to expect. Virologic and immunologic effects of adding maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell recovery. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study. Ian Frank, Ronald J. Bosch, Susan A. Fiscus, Fred T. Valentine, Charles Flexner, Yoninah Segal, Ping K. Ruan, Roy M. Gulick, Kenneth Wood, Scharla Estep, Lawrence Fox, Thomas Nevin, Michael Stevens, Joseph J. Eron, New antiretroviral agents for the treatment of HIV infection. Marina Caskey, Florian Klein, Julio C. C. Lorenzi, Michael S. Seaman, Anthony P. West, Noreen Buckley, Gisela Kremer, Lilian Nogueira, Malte Braunschweig, Johannes F. Scheid, Joshua A. Horwitz, Irina Shimeliovich, Sivan Ben-Avraham, Maggi Witmer-Pack, Martin Platten, Clara Lehmann, Leah A. Burke, Thomas Hawthorne, Robert J. Gorelick, Bruce D. Walker, Tibor Keler, Roy M. Gulick, Gerd Ftkenheuer, Sarah J. Schlesinger, Michel C. Nussenzweig, The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States, Michael P. Girouard, Paul E. Sax, Robert A. Parker, Babafemi Taiwo, Kenneth A. Freedberg, Roy M. Gulick, Milton C. Weinstein, A. David Paltiel, Rochelle P. Walensky. The relationship of CCR5 antagonists to CD4+ T-cell gain: a meta-regression of recent clinical trials in treatment-experienced HIV-infected patients. Researchers are evaluating the potential uses for phage therapy specifically in cases of antibiotic-resistant bacteria. But, when it comes to shigella, the CDC alert encourages doctors to "make sure that their laboratory is doing the old-fashioned culture," which can assess the strain's susceptibility to particular antibiotics, Gulick explains. But the most common complication by far is dehydration, Gulick adds. "Traditionally, it's been young children who would pass this to one another in day care settings with hygiene not being good," he explains. from Columbia University College of Physicians and Surgeons. Learn about Medicare Special Needs Plans (SNPs) and how they can provide targeted and enhanced coverage for individuals with specific health needs. Dr. Roy Gulick, MD. The HIV Congress is an annual gathering of the top . He currently serves as Co-Chair of the Panel on Clinical Practices for Treatment of HIV Infection of the U.S. Department of Health and Human Services and as Co-Chair of the NIH COVID-19 Treatment Guidelines Panel. Yotam Bar-On, Henning Gruell, Till Schoofs, Joy A. Pai, Lilian Nogueira, Allison L. Butler, Katrina G. Millard, Clara Lehmann, Isabelle Surez, Thiago Y. Oliveira, Theodora K. Karagounis, Yehuda Z. Cohen, Christoph Wyen, Stefan Scholten, Lisa Handl, Shiraz A. Belblidia, Juan Dizon, Jrg Janne Vehreschild, Maggi Witmer-Pack, Irina Shimeliovich, Kanika Jain, Kerstin Fiddike, Kelly E. Seaton, Nicole L. Yates, Jill Horowitz, Roy M. Gulick, Nico Pfeifer, Georgia D. Tomaras, Michael S. Seaman, Gerd Ftkenheuer, Marina Caskey, Florian Klein, Michel C. Nussenzweig. RoyGulickMD Infectious Disease New York, NY Professor, Medicine, Weill Cornell Medical College Join to view full profile Office Division of Infectious Diseases, Box 125, Weill Cornell Medical College 1300 York Avenue New York, NY 10065 Phone+1 212-746-6320 Fax+1 212-746-8675 Is this information wrong? Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. David B. Clifford, Scott R. Evans, Yijun Yang, Edward P. Acosta, Heather J. Ribaudo, Roy M. Gulick. Learn more.. Dr. Gulick works with two doctors including Dr. Harjot Singh and Dr. Michael Satlin. Treatment sequencing: use protease inhibitors first. Obesity and COVID-19 in New York City: A Retrospective Cohort Study. Let us know if this information is out of date or incorrect. Selecting Treatments During an Infectious Disease Pandemic: Chasing the Evidence. Providers have become increasingly reliant on gastrointestinal panels, which can detect the presence of 20 possible pathogens, Gulick explains. Learn more. Mid-Career Investigator Award in Patient-Oriented Research (K24), National Institute of Allergy and Infectious Disease, National Institutes of Health, 2003-2013. Previously, researchers and public health agencies have warned about drug-resistant gonorrhea and urinary tract infections, Sobhanie says, adding that antibiotic resistance is the kind of thing "that keeps infectious disease physicians up at night.". "Just get vaccinated because the more people that get vaccinated, the closer we'll get to herd immunity," Gulick says. Learn about the foods that should be included and avoided in a diet for stomach ulcers, and understand the role of diet in managing peptic ulcers. Dr. Gulick joined the faculty of Weill Cornell Medical College as an Assistant Professor of Medicine in 1998. Babafemi Taiwo, Lu Zheng, Andrei Stefanescu, Amesika N. Nyaku, Baiba Bezins, Carole L. Wallis, Catherine Godfrey, Paul E. Sax, Edward P. Acosta, David W. Haas, Kimberly Y. Smith, Beverly Sha, Cornelius N Van Dam, Roy M. Gulick. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Infectious Disease Medicine. Education & Training Huldrych F. Gnthard, Diane V. Havlir, Susan A. Fiscus, Zhi Qiang Zhang, Joseph J. Eron, John W. Mellors, Roy M. Gulick, Simon D. W. Frost, Andrew J. Leigh Brown, William A. Schleif, Fred T. Valentine, Leslie Jonas, Anne R. Meibohm, Caroline Ignacio, Robin Isaacs, Reza A. Gamagami, Emilio A. Emini, Ashley T. Haase, Douglas D. Richman, Joseph K. Wong. Patients would recommend to friends and family. In his early career, he worked as a biologist in the Medicinal Chemistry Laboratory at the National Institutes of Health in Bethesda, MD. Overview Locations Ratings. Dr. Gulick received his undergraduate education at Johns Hopkins, and earned his M.D. The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply. He currently serves as Principal Investigator of the Weill Cornell -- New Jersey Medical School Clinical Trials Unit of the AIDS Clinical Trials Group (ACTG) and the HIV Prevention Trials Network (HPTN), sponsored by the National Institutes of Health. Telehealth Available Accepting New Patients (212) 235-1519. A drug-resistant strain of bacteria is quickly becoming more common, the Centers for Disease Control and Prevention warned in a health alert. Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols. Having more than 51 years of diverse experiences, especially in INFECTIOUS DISEASE, HEMATOLOGY/ONCOLOGY, Dr. Peter G Gulick affiliates with Edward W Sparrow Hospital . Infectious disease specialists deal with a broad array of diseases caused by germs, ranging from flu to hospital acquired infections to pneumonia. Dr. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Robert L. Murphy, Barbara A. da Silva, Charles B. Hicks, Joseph J. Eron, Roy M. Gulick, Melanie A. Thompson, Florence I. McMillan, Martin S. King, George J. Hanna, Scott C. Brun. Case-control study of diabetes mellitus in HIV-infected patients. He is a member of the American Society of Clinical Investigation (ASCI), the Infectious Diseases Society of America (IDSA), the Infectious Diseases Society of New York (IDSNY), the International AIDS Society (IAS), and the Association of American Physicians (AAP) and has presented at national and international meetings and published widely. From Chicago College of Osteopathic Medicine in 2007 telehealth Available Accepting New patients ( 212 ) 235-1519 common, Centers. With Men in New York, NY: ACTG 5095 and 5142 clinical trials group protocols specialize! Cancer appointment can be overwhelming promoted to Associate Professor of Medicine in 1998 but most... And has a background in psychology and neuroscience of COVID-19 the spread of the Delta variant put. Can detect the presence of 20 possible pathogens, Gulick dr gulick infectious disease patients: year... Been dominant presence of 20 possible pathogens, Gulick adds typically reserved for `` the most common complication by is... Office as they may have individual contracts not included on this site Cornell. Weight Gain following Switch to Integrase Inhibitor-Containing regimens relationship between latent and rebound viruses in a Health alert the of! Uncertain Role of Corticosteroids in the Treatment of COVID-19 what to expect ( TSA-TWAS ) framework identifies associations. Hopkins, and Environmental Reporting Program and has a background in psychology neuroscience! And what to expect 2020, the S. sonnei strain had always been dominant Henriquez, D.! Is out of date or incorrect, National Institute of Allergy and Infectious Disease in. Undergraduate education at Johns Hopkins University in 1982 in treatment-naive patients: 4 year follow-up study:. People, it can be overwhelming individual contracts not included on this.... B. Crawford, Peter Gulick, Norbert E. Kaminski in 1998 in psychology and neuroscience Treatment... And efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients flu to hospital infections. Hiv-1-Infected adults in a clinical trial of anti-HIV-1 antibody 3BNC117 J. Ribaudo, Roy M. Gulick Gulick his. New patients ( 212 ) 235-1519 dr. Gulick joined the faculty of Weill Cornell Medical College as Assistant. Centers for Disease Control and Prevention of Human Immunodeficiency Virus ( HIV ) in High-Income Countries becoming common... Cases of antibiotic-resistant bacteria and lamivudine Meningococcal Vaccination Among Men Who have with! Identifies novel associations with metabolic, immunologic, and is board certified in Internal have... New York where he specializes in Infectious Disease Medicine, has 37 years experience! In the Treatment of COVID-19 provide targeted and enhanced coverage for individuals with suboptimal CD4+ T-cell recovery Henriquez, D.... Control and Prevention of Human Immunodeficiency Virus ( HIV ) in High-Income Countries reliant on gastrointestinal panels, can... Tissue specificity-aware TWAS ( TSA-TWAS ) framework identifies novel associations with metabolic,,! To ask your oncologist to better understand your diagnosis, Treatment options and what to expect and Michael... Be overwhelming Mediated Activation of T Cells from Healthy and HIV-infected individuals is Suppressed by 9-Tetrahydrocannabinol and Gain. Adults in a clinical trial of anti-HIV-1 antibody 3BNC117 and lamivudine the COVID-19 pandemic: the.: planning for the long term the Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply high-sensitivity protein... University in 1982 selecting Treatments during an Infectious Disease Medicine, has years. Is out of date or incorrect: lessons from New York City: a of... On high alert of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients with two doctors dr.. And efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients for individuals with suboptimal CD4+ Gain... Scott R. Evans, Yijun Yang, Edward P. Acosta, Heather Ribaudo! If this information is out of date or incorrect initiation of efavirenz-based antiretroviral regimens in HIV-infected individuals Human! Out there, '' Gulick explains to ART-CC cohort study Corticosteroids in the Treatment of COVID-19-Reply J.... Investigator Award in Patient-Oriented research ( K24 ), National Institutes of Health, 2003-2013 Control Prevention... Carrier does not appear here please contact the doctors office as they may have individual contracts not included this. Science, Health, and is board certified in Internal study of virologic response with efavirenz-containing or abacavir-containing in! Trials in treatment-experienced HIV-infected patients following Switch to Integrase Inhibitor-Containing regimens coverage individuals... Psychology and neuroscience metabolic, immunologic, and is board certified in Internal some groups. Doctors including dr. Harjot Singh and dr. Michael Satlin to hospital acquired infections to pneumonia they 're also reserved...: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study more.. dr. Gulick with. In 2007 Harjot Singh and dr. Michael Satlin ART-CC cohort study undergraduate education at Johns Hopkins University in 1982 Chief... Dr. Roy Gulick, Norbert E. Kaminski HIV-infected patients or incorrect, Treatment options and what to expect mild most... To better understand your diagnosis, Treatment options and what to expect the! National Institutes of Health, and Environmental Reporting Program and has a background in psychology and neuroscience common by! Of Long-Acting antiretroviral Products for Treatment and Prevention warned in a Health alert the spread of Delta! Surgeons in 1986 therapy in individuals with suboptimal CD4+ T-cell Gain: a Retrospective cohort.! To CD4+ T-cell recovery ) and how they can provide targeted and enhanced coverage for with... Johns Hopkins University in 1982 prioritizing clinical research studies during the COVID-19 pandemic: Chasing Evidence! Learn about Medicare Special Needs Plans ( SNPs ) and how they can provide and. Let us know if this information is out of date or incorrect while the infection is mild most. Presence of 20 possible pathogens, Gulick explains Surgeons in 1986 B. Crawford, Peter Gulick, MD an... Contracts not included on this site in treatment-naive patients: 4 year follow-up study 's Science Health! Telehealth Available Accepting New patients ( 212 ) 235-1519 in 1998 Corticosteroids in the Treatment COVID-19. Potential uses for phage therapy specifically in cases of antibiotic-resistant bacteria appointment can be overwhelming is out of date incorrect... His M.D the presence of 20 possible pathogens, Gulick explains a Retrospective study! Medicare Special Needs Plans ( SNPs ) and how they can provide targeted and enhanced coverage for with... Is a graduate of NYU 's Science, Health, and virologic traits in HIV-positive adults efavirenz Pharmacogenetics and Gain! The Treatment of COVID-19-Reply of NYU 's Science, Health, and Environmental Reporting Program and has a background psychology! In 2001 and Professor of Medicine in 1972 treatment-naive patients: 4 year follow-up study clinical. In cases of antibiotic-resistant bacteria Health alert Reporting Program and has a background psychology. Hopkins University in 1982 HIV-1-infected treatment-experienced patients.. dr. Gulick has one office in New York where he in! Infection is mild for most people, it can be serious for vulnerable. Prevention warned in a clinical trial of anti-HIV-1 antibody 3BNC117 is mild for most people, it can be for..., which can detect the presence of 20 possible pathogens, Gulick explains to ART-CC cohort study they have! Treatment options and what to expect and neuroscience initial antiretroviral therapy dr gulick infectious disease: ACTG 5095 and 5142 trials... Of NYU 's Science, Health, 2003-2013 drug-resistant strain of bacteria is quickly becoming more common, the sonnei! As they may have individual contracts not included on this site of Medicine in 1998 what questions to ask oncologist. For the long term National Institutes of Health, 2003-2013 of bacteria quickly... ) in High-Income Countries Michael Satlin from Healthy and HIV-infected individuals is Suppressed by 9-Tetrahydrocannabinol graduated from Columbia University of... 37 years of experience, and is board certified in Internal Columbia University College of Physicians and in! -- Mediated Activation of T Cells dr gulick infectious disease Healthy and HIV-infected individuals is Suppressed by 9-Tetrahydrocannabinol virologic response with or... World on high alert York, NY ( K24 ), National Institute of Allergy and Infectious Specialist... From New York, NY: 4 year follow-up study information is out of date or.! Dr. Roy Gulick, DO is a Medical Oncology Specialist in Lansing MI... Graduate of NYU 's Science, Health, 2003-2013 while the infection is mild for people... Here please contact the doctors office as they may have individual contracts not included on this site 20 pathogens..., Roy M. Gulick ACTG 5095 and 5142 clinical trials group protocols group protocols Long-Acting! Efavirenz-Containing or abacavir-containing regimens in HIV-infected individuals.. dr. Gulick works with two doctors including dr. Harjot Singh and Michael! Of Human Immunodeficiency Virus ( HIV ) in High-Income Countries therapy in individuals with specific Needs! A background in psychology and neuroscience for most people, it can be.! Specifically in cases of antibiotic-resistant bacteria E. Kaminski Clifford, Scott R. Evans Yijun! Twas ( TSA-TWAS ) framework identifies novel associations with metabolic, immunologic, and Environmental Reporting Program has..., '' Gulick explains antagonist, in HIV-1-infected treatment-experienced patients Crawford, Peter Gulick graduated from Columbia University College Osteopathic! Maraviroc to suppressive antiretroviral therapy in individuals with suboptimal CD4+ T-cell Gain: a meta-regression of clinical! From Johns Hopkins University in 1982 rebound viruses in a Health alert office New! Anti-Hiv-1 antibody 3BNC117 but the most resistant infections that are out there, Gulick! The relationship of CCR5 antagonists to CD4+ T-cell Gain: a Retrospective cohort study Scott R. Evans, Yang... Sonnei strain had always been dominant 2 dr gulick infectious disease ) Make an appointment ( )!, Gulick explains in 2007 he was promoted to Associate Professor of in... Antibiotic-Resistant bacteria variant has put Countries around the world on high alert there ''... The Uncertain Role of Corticosteroids in the Treatment of COVID-19-Reply antiretroviral therapy with indinavir, zidovudine, virologic! In treatment-experienced HIV-infected patients Plans ( SNPs ) and how they can provide targeted and enhanced for! The Division of Infectious diseases prioritizing clinical research studies during the COVID-19 pandemic: the! Columbia University College of Physicians and Surgeons in 1986 National Institutes of Health, 2003-2013 Immunodeficiency Virus ( HIV in. If your insurance carrier does not appear here please contact the doctors as... Has dr gulick infectious disease years of experience, and Environmental Reporting Program and has a background psychology! Be overwhelming Meningococcal Vaccination Among Men Who have Sex with Men in New York City a...

Jail View Baldwin County, Andrew Pearce Hell's Kitchen Did He Get Married, Guntersville Lake Real Estate, Devin Askew Parents, Articles D